Prot #RD.03.SPR.104003: A Randomized, Double-Blind, Multi-Centre, Placebo-Controlled, Parallel-Arm Phase 2 Trial to Assess Safety, Efficacy and Pharmacokinetics of CD11301 0.03% and 0.06% Gel in the Treatment of Cutaneous T-Cell Lymphoma (CTCL), Stages IA

Project: Research project

Project Details

Effective start/end date3/20/183/20/21


  • Premier Research International, LLC (Prot #RD.03.SPR.104003 // Prot #RD.03.SPR.104003)
  • Galderma Research & Development, SNC (Prot #RD.03.SPR.104003 // Prot #RD.03.SPR.104003)